Suppr超能文献

非皮质醇分泌性肿瘤患者腹膜后腹腔镜下单侧肾上腺腺瘤切除术后的糖皮质激素替代治疗:一项回顾性队列研究

Glucocorticoid replacement therapy after retroperitoneal laparoscopic unilateral adrenal adenoma resection in patients with non-cortisol secreting tumors: a retrospective cohort study.

作者信息

Ren Ruimin, Han Haoran, Ma Jing, Wu Jinfeng, Shang Jiwen, Parameswaran Rajeev, Araujo-Castro Marta, Ma Ding

机构信息

Department of Urology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.

Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

出版信息

Gland Surg. 2024 Nov 30;13(11):2189-2197. doi: 10.21037/gs-24-469. Epub 2024 Nov 26.

Abstract

BACKGROUND

Adrenal Cushing's syndrome is caused by an adrenal tumor that produces hypercortisolism and requires glucocorticoid supplementation following resection of the tumour to prevent adrenal insufficiency. Few studies have examined whether glucocorticoid replacement (GR) therapy is required after retroperitoneal laparoscopic unilateral adrenal adenoma resection in patients with non-cortisol secreting tumors, or whether there is any correlation between preoperative biochemical indicators and postoperative cortisol function. This study sought to investigate which patients with non-cortisol secreting tumors required GR therapy after undergoing retroperitoneal laparoscopic resection of unilateral adrenal cortical adenoma.

METHODS

This retrospective case-control study included patients who underwent unilateral adrenalectomy, and who had a postoperative pathological diagnosis of adrenal cortical adenoma. Including primary aldosteronism and non-functional adrenal adenoma. In total, 35 patients were included in the study, of whom 12 were male and 23 were female. All the patients successfully underwent retroperitoneal laparoscopy. The adrenal adenoma resection patients were divided into the following two groups based on whether they received GR therapy after surgery: (I) the no GR group, which comprised 28 patients; and (II) the GR group, which comprised 7 patients. Routine preoperative, adrenal-related, basal serum cortisol, and plasma adrenocorticotropic hormone (ACTH) tests were conducted, and the percentage of eosinophils, and the number of eosinophils were assessed each morning for 3 days after surgery. Repeated measures analysis of variance was used, and the value was the main statistic used to test for differences between groups, which was used to evaluate the magnitude of differences between groups.

RESULTS

Before surgery, except for the ACTH level which showed a statistically significant difference between the two groups (P=0.04), there were no statistically significant differences between the two groups (P>0.05) in terms of eosinophil percentage, eosinophil count, serum potassium level, serum sodium level, cortisol levels (8 am, 4 pm, 12 am), and renin-angiotensin II-aldosterone levels (recumbent/standing), among others. After surgery, there were significant differences between the two groups in terms of the morning basal serum cortisol level (at 8 am) and the ACTH level (25.037, P<0.001; 12.033, P=0.001), but no significant differences in the percentage and number of eosinophils were observed between the two groups. After laparoscopic adrenal adenoma resection, patients' cortisol levels are low on the first postoperative day, but most adrenal cortisol levels respond well to ACTH stimulation. On the second and third days after surgery, patients' cortisol levels generally return to normal without GR therapy. However, for patients with continuously low levels of cortisol and ACTH 3 days after surgery, supplemental glucocorticoids should be actively given in the early postoperative stage.

CONCLUSIONS

This study preliminarily showed that postoperative cortisol and ACTH levels can be used to identify patients at an increased risk of hypocortisolism after unilateral adrenal adenoma surgery, and to guide the use of GR therapy.

摘要

背景

肾上腺库欣综合征由肾上腺肿瘤导致皮质醇增多症引起,肿瘤切除后需要补充糖皮质激素以预防肾上腺功能不全。很少有研究探讨非皮质醇分泌性肿瘤患者行腹膜后腹腔镜单侧肾上腺腺瘤切除术后是否需要糖皮质激素替代(GR)治疗,以及术前生化指标与术后皮质醇功能之间是否存在相关性。本研究旨在调查哪些非皮质醇分泌性肿瘤患者在接受腹膜后腹腔镜单侧肾上腺皮质腺瘤切除术后需要GR治疗。

方法

本回顾性病例对照研究纳入了接受单侧肾上腺切除术且术后病理诊断为肾上腺皮质腺瘤的患者。包括原发性醛固酮增多症和无功能肾上腺腺瘤。本研究共纳入35例患者,其中男性12例,女性23例。所有患者均成功接受腹膜后腹腔镜手术。肾上腺腺瘤切除患者根据术后是否接受GR治疗分为以下两组:(I)无GR组,共28例患者;(II)GR组,共7例患者。进行常规术前、肾上腺相关、基础血清皮质醇和血浆促肾上腺皮质激素(ACTH)检测,并在术后3天每天早晨评估嗜酸性粒细胞百分比和嗜酸性粒细胞数量。采用重复测量方差分析,P值是用于检验组间差异的主要统计量,用于评估组间差异的大小。

结果

术前,除两组间ACTH水平差异有统计学意义(P=0.04)外,两组在嗜酸性粒细胞百分比、嗜酸性粒细胞计数、血清钾水平、血清钠水平、皮质醇水平(上午8点、下午4点、凌晨12点)以及肾素-血管紧张素II-醛固酮水平(卧位/立位)等方面差异均无统计学意义(P>0.05)。术后,两组在早晨基础血清皮质醇水平(上午8点)和ACTH水平方面差异有统计学意义(25.037,P<0.001;12.033,P=0.001),但两组间嗜酸性粒细胞百分比和数量差异无统计学意义。腹腔镜肾上腺腺瘤切除术后,患者术后第1天皮质醇水平较低,但大多数肾上腺皮质醇水平对ACTH刺激反应良好。术后第2天和第3天,患者皮质醇水平在未接受GR治疗的情况下一般恢复正常。然而,对于术后3天皮质醇和ACTH水平持续较低的患者,术后早期应积极给予补充糖皮质激素。

结论

本研究初步表明,术后皮质醇和ACTH水平可用于识别单侧肾上腺腺瘤手术后发生皮质醇减少症风险增加的患者,并指导GR治疗的使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edce/11635575/382a4ae9b5a0/gs-13-11-2189-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验